Cyclooxygenase inhibitors: scope of their use and development in cancer chemotherapy (Q37646513)

21 August 2017

1 reference

title

Cyclooxygenase inhibitors: scope of their use and development in cancer chemotherapy (English)

1 reference

21 August 2017

1 reference

Mohammed Naseer A Khan

series ordinal

1

1 reference

21 August 2017

Yong Sup Lee

series ordinal

2

1 reference

21 August 2017

publication date

1 March 2011

1 reference

Medicinal Research Reviews

21 August 2017

published in

1 reference

21 August 2017

volume

31

1 reference

21 August 2017

issue

2

1 reference

21 August 2017

page(s)

161-201

1 reference

Why there are two cyclooxygenase isozymes

21 August 2017

cites work

1 reference

Differential regulation of cyclooxygenases 1 and 2 by interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts

21 January 2018

1 reference

Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2

21 January 2018

1 reference

COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression

21 January 2018

1 reference

Is no NSAID a good NSAID? Approaches to NSAID-associated upper gastrointestinal disease

21 January 2018

1 reference

Evaluation of effects of rofecoxib on platelet function in an in vitro model of thrombosis with circulating human blood

21 January 2018

1 reference

Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin

21 January 2018

1 reference

Cardiovascular effects of selective cyclooxygenase-2 inhibitors

21 January 2018

1 reference

Deleterious effects of prostaglandin E2 in oesophageal carcinogenesis.

21 January 2018

1 reference

Cyclo-oxygenase-2 and its inhibition in cancer: is there a role?

21 January 2018

1 reference

Cyclooxygenase-2 as a target for anticancer drug development

21 January 2018

1 reference

Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?

21 January 2018

1 reference

Carcinogen substrate specificity of human COX-1 and COX-2.

21 January 2018

1 reference

Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential

21 January 2018

1 reference

Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522

21 January 2018

1 reference

Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues

21 January 2018

1 reference

Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas

21 January 2018

1 reference

A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer

21 January 2018

1 reference

Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention

21 January 2018

1 reference

Primary chemoprevention of familial adenomatous polyposis with sulindac

21 January 2018

1 reference

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

21 January 2018

1 reference

Enhancement of colon carcinogenesis by prostaglandin E2 administration

21 January 2018

1 reference

Selective COX-2 inhibitor, NS-398, inhibits the replicative senescence of cultured dermal fibroblasts

21 January 2018

1 reference

Effect of NS-398 on colon cancer cells

21 January 2018

1 reference

Colon cancer cells with high invasive potential are susceptible to induction of apoptosis by a selective COX-2 inhibitor.

21 January 2018

1 reference

Sequence-dependent effect of a cyclooxygenase-2 inhibitor on topoisomerase I inhibitor and 5-fluorouracil-induced cytotoxicity of colon cancer cells

21 January 2018

1 reference

New mechanisms and therapeutic potential of curcumin for colorectal cancer.

21 January 2018

1 reference

The molecular mechanisms for the antitumorigenic effect of curcumin

21 January 2018

1 reference

Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents

21 January 2018

1 reference

The effect of turmeric extracts on inflammatory mediator production

21 January 2018

1 reference

Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase

21 January 2018

1 reference

Curcumin mediates ceramide generation via the de novo pathway in colon cancer cells.

21 January 2018

1 reference

Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells

21 January 2018

1 reference

Cancer chemopreventive effects of curcumin

21 January 2018

1 reference

Curcumin for chemoprevention of colon cancer

21 January 2018

1 reference

Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells

21 January 2018

1 reference

Synergistic inhibitory effects of curcumin and 5-fluorouracil on the growth of the human colon cancer cell line HT-29.

21 January 2018

1 reference

Selenium regulates cyclooxygenase-2 and extracellular signal-regulated kinase signaling pathways by activating AMP-activated protein kinase in colon cancer cells.

21 January 2018

1 reference

Chemoprevention of colon cancer by organoselenium compounds and impact of high- or low-fat diets.

21 January 2018

1 reference

Chemoprevention of familial adenomatous polyposis development in the APC(min) mouse model by 1,4-phenylene bis(methylene)selenocyanate

21 January 2018

1 reference

Molecular targets of the chemopreventive agent 1,4-phenylenebis (methylene)-selenocyanate in human non-small cell lung cancer

21 January 2018

1 reference

The production of prostanoids in human cancers, and their implications for tumor progression

21 January 2018

1 reference

COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ

21 January 2018

1 reference

Prostaglandin E2 regulates aromatase activity and expression in human adipose stromal cells via two distinct receptor subtypes

21 January 2018

1 reference

Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells.

21 January 2018

1 reference

Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition

21 January 2018

1 reference

Spectral and crystallographic study of pyridinic analogues of nimesulide: determination of the active form of methanesulfonamides as COX-2 selective inhibitors

21 January 2018

1 reference

Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): rationale for selective inhibition and progress to date

21 January 2018

1 reference

Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).

21 January 2018

1 reference

Pharmacological analysis of cyclooxygenase-1 in inflammation

21 January 2018

1 reference

Effect of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of lung tumors and their expression of cyclooxygenase-2 and peroxisome proliferator- activated receptor-gamma

21 January 2018

1 reference

Synthesis and biological evaluation of novel sulfonanilide compounds as antiproliferative agents for breast cancer

21 January 2018

1 reference

Cyclooxygenase-2 inhibitor SC-236 [4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1-pyrazol-1-l] benzenesulfonamide] suppresses nuclear factor-kappaB activation and phosphorylation of p38 mitogen-activated protein kinase, extracellular signal-regulated k

21 January 2018

1 reference

Cyclo-oxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer

21 January 2018

1 reference

Synthesis and pharmacological evaluation of 1H-imidazoles as ligands for the estrogen receptor and cytotoxic inhibitors of the cyclooxygenase

21 January 2018

1 reference

2,3,5-Substituted tetrahydrofurans: COX-2 inhibitory activities of 5-hydroxymethyl-/carboxyl-2,3-diaryl-tetrahydro-furan-3-ols

21 January 2018

1 reference

Tumor cell proliferation and cyclooxygenase enzyme inhibitory compounds in Amaranthus tricolor

21 January 2018

1 reference

Synthesis and biological activities of novel dexibuprofen tetraacetylriboflavin conjugates.

21 January 2018

1 reference

Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells

21 January 2018

1 reference

The role of cyclooxygenase-2 in prostate cancer

21 January 2018

1 reference

Expression, subcellular localization and putative function of platelet-type 12-lipoxygenase in human prostate cancer cell lines of different metastatic potential

21 January 2018

1 reference

New NSAIDs-NO hybrid molecules with antiproliferative properties on human prostatic cancer cell lines.

21 January 2018

1 reference

New COX-2/5-LOX inhibitors: apoptosis-inducing agents potentially useful in prostate cancer chemotherapy

21 January 2018

1 reference

Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer.

21 January 2018

1 reference

Prognostic role of the ratio between cyclooxygenase-2 in tumor and stroma compartments in cervical cancer.

21 January 2018

1 reference

Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer: correlation with clinical outcome

21 January 2018

1 reference

Cyclooxygenase-2 interacts with p53 and interferes with p53-dependent transcription and apoptosis.

21 January 2018

1 reference

Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma

21 January 2018

1 reference

Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers

21 January 2018

1 reference

Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice

21 January 2018

1 reference

Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer

21 January 2018

1 reference

Design and synthesis of subtype-selective cyclooxygenase (COX) inhibitors derived from thalidomide.

21 January 2018

1 reference

Anti-angiogenic activity of basic-type, selective cyclooxygenase (COX)-1 inhibitors

21 January 2018

1 reference

Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung.

21 January 2018

1 reference

Cyclooxygenase-2 in human non-small cell lung cancer

21 January 2018

1 reference

The role of COX-2 inhibitors in lung cancer

21 January 2018

1 reference

Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study

21 January 2018

1 reference

Extract from Scutellaria baicalensis Georgi attenuates oxidant stress in cardiomyocytes.

21 January 2018

1 reference

The anticancer activities of wogonin in murine sarcoma S180 both in vitro and in vivo

21 January 2018

1 reference

Protective role of wogonin against lipopolysaccharide-induced angiogenesis via VEGFR-2, not VEGFR-1.

21 January 2018

1 reference

Wogonin inhibits inducible prostaglandin E(2) production in macrophages

21 January 2018

1 reference

Protein kinase C and other diacylglycerol effectors in cancer

21 January 2018

1 reference

Suppression of cyclooxygenase-2 expression of skin fibroblasts by wogonin, a plant flavone from Scutellaria radix

21 January 2018

1 reference

Inhibition of prostaglandin production by a structurally-optimized flavonoid derivative, 2',4',7-trimethoxyflavone and cellular action mechanism

21 January 2018

1 reference

Wogonin, a bioactive flavonoid in herbal tea, inhibits inflammatory cyclooxygenase-2 gene expression in human lung epithelial cancer cells

21 January 2018

1 reference

Cancer chemopreventive activity of resveratrol, a natural product derived from grapes

21 January 2018

1 reference

Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells

21 January 2018

1 reference

Cyclooxygenase-2 expression in hamster and human pancreatic neoplasia

21 January 2018

1 reference

Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors

21 January 2018

1 reference

Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer

21 January 2018

1 reference

A cyclooxygenase-2 inhibitor, nimesulide, inhibits postinitiation phase of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters

21 January 2018

1 reference

Cyclooxygenase-2 expression in human pancreatic adenocarcinomas

21 January 2018

1 reference

A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer

21 January 2018

1 reference

Chemopreventive effects of a selective cyclooxygenase-2 inhibitor (etodolac) on chemically induced intraductal papillary carcinoma of the pancreas in hamsters

21 January 2018

1 reference

Inhibition of COX-2 and activation of peroxisome proliferator-activated receptor gamma synergistically inhibits proliferation and induces apoptosis of human pancreatic carcinoma cells

21 January 2018

1 reference

Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis

21 January 2018

1 reference

Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer.

21 January 2018

1 reference

The role of cyclooxygenases in inflammation, cancer, and development

21 January 2018

1 reference

Chemoprevention of gastric cancer by celecoxib in rats.

21 January 2018

1 reference

The anti-cancer effect of COX-2 inhibitors on gastric cancer cells

21 January 2018

1 reference

Anticancer effect of celecoxib via COX-2 dependent and independent mechanisms in human gastric cancers cells.

21 January 2018

1 reference

Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells

21 January 2018

1 reference

Induction of apoptosis by cyclo-oxygenase-2 inhibitor NS398 through a cytochrome C-dependent pathway in esophageal cancer cells

21 January 2018

1 reference

Inhibition of ultraviolet B-induced activator protein-1 (AP-1) activity by aspirin in AP-1-luciferase transgenic mice

21 January 2018

1 reference

Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: evidence for growth suppression by inhibiting COX-2 expression

21 January 2018

1 reference

Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition

21 January 2018

1 reference

Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice

21 January 2018

1 reference

Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis

21 January 2018

1 reference

In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells

21 January 2018

1 reference

In-vivo effects and mechanisms of celecoxib-reduced growth of cyclooxygenase-2 (COX-2)-expressing versus COX-2-deleted human HCC xenografts in nude mice

21 January 2018

1 reference

Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway.

21 January 2018

1 reference

Novel target for induction of apoptosis by cyclo-oxygenase-2 inhibitor SC-236 through a protein kinase C-beta(1)-dependent pathway

21 January 2018

1 reference

The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2

21 January 2018

1 reference

Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents

21 January 2018

1 reference

Enhanced growth inhibition and apoptosis induction in NSCLC cell lines by combination of celecoxib and 4HPR at clinically relevant concentrations

21 January 2018

1 reference

Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs

21 January 2018

1 reference

Cyclooxygenase-2 inhibitors demonstrate anti-proliferative effects in oesophageal cancer cells by prostaglandin E(2)-independent mechanisms

21 January 2018

1 reference

Nimesulide inhibits IFN-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells by COX-2 and PGE2 independent mechanisms

21 January 2018

1 reference

NS-398, ibuprofen, and cyclooxygenase-2 RNA interference produce significantly different gene expression profiles in prostate cancer cells

21 January 2018

1 reference

A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer

21 January 2018

1 reference

Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer

21 January 2018

1 reference

A phase II study of carboplatin and paclitacel with meloxicam

21 January 2018

1 reference

Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer

21 January 2018

1 reference

Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma

21 January 2018

1 reference

Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma

21 January 2018

1 reference

Curcumin: from ancient medicine to current clinical trials.

21 January 2018

1 reference

Cytotoxic and COX-2 Inhibition Properties of Hydroxycinnamic Derivatives

21 January 2018

1 reference

Converting p53 from a killer into a healer

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MED.20182

1 reference

21 August 2017

1 reference